Viridian Therapeutics shares are trading higher after the company reported Q4 financial results. Wedbush maintained an Outperform rating on the stock and raised its price target from $39 to $40.
Portfolio Pulse from Benzinga Newsdesk
Viridian Therapeutics' stock price increased following the announcement of their Q4 financial results. Additionally, Wedbush reaffirmed an Outperform rating and increased the price target for VRDN from $39 to $40.
February 28, 2024 | 5:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viridian Therapeutics' shares rose after reporting Q4 results, with Wedbush maintaining an Outperform rating and raising the price target from $39 to $40.
The positive Q4 financial results directly contribute to the stock's upward movement. The reaffirmation of an Outperform rating and an increased price target by a reputable analyst firm like Wedbush further supports investor confidence, likely leading to a short-term positive impact on VRDN's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100